This class of drugs harnesses the immune system for the fight against aberrant cancer cells by inhibiting co-inhibitory signals (immune checkpoints) allowing the undamped response of cytotoxic CD8+ T lymphocytes (CTL) to the cancer cells. This evidence concerns the gene CD8A and cancer.